Creating new generation diagnostics for precision medicine
We identify and characterize proteins, protein modifications and protein interactions that can serve as biomarkers for various physiological and disease conditions
We develop automatable mass spectrometry-based methods to quantify biomarkers with high specificity, sensitivity and reproducibility
We quantify variations in biomarker levels across patient cohorts and establish correlations with physiological conditions, disease progression, response to treatment, etc.
We make our methods publicly available through publication in scientific journals immediately after validation, some being made available to health centers and clinics through our corporate partner Nuclea Biotechnology (Cambridge, USA)
Our methods contribute to the development of precision medicine for the benefit of patients around the world